Multiple myeloma (MM) is an incurable disease that is characterized by the accumulation of clonal plasmocytes in the bone marrow. It accounts for 10-15% of all hemato logical malignancies and 1-2% of all cancers. The incidence of MM varies by race and age. It occurs in Europe in approximately 4 of every 100,000 individuals. 1 In Poland about 1000 new cases of MM are diagnosed yearly, however this number seems to be underestimated. To date, no single cause for myeloma has been identified.
In Treatment of myeloma Treatment of MM is an extremely complex process. In the last years the treatment of newly diagnosed MM patients has undergone significant changes. 5, 6 The initial decision for newly diagnosed patients is based on whether a patient is a candidate for high-dose chemotherapy supported by stem cell transplantation. 7, 8 Afterwards the options are often dependent on the previous treatment.
Autologous stem cell transplantation High-dose chemotherapy supported by auto logous stem cell transplantation is associated with an increased complete remission (CR) rate and an increase in median overall survival compared to standard dose chemotherapy and it is now considered the treatment of choice for newly diagnosed MM patients <65 years. Until now this is a therapy that has clearly demonstrated a prolongation of overall survival compared with conventional chemotherapy. 5, 6 In the past 20 years peripheral blood stem cell transplantation (PBSCT) has been widely used as a part of starting therapy in newly diagnosed MM and as a salvage therapy for patients with recurrent/resistant disease. Although PBSCT is superior to conventional therapy, it is still not a therapeutic option. 5
Allogeneic stem cell transplantation Allogeneic stem cell transplantation is at present the only available option which is curative, however this approach involves a mortality of more than 20-30%. To diminish such a high percentage of mortality the French group IFM tested
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Multiple myeloma is still an incurable disease. In recent years the introduction of 3 novel drugs oriented on basic mechanisms of multiple myeloma cells proliferation and survival has improved patients' outcome. These drugs are: thalidomide, its new analog, lenalidomide, and proteasome inhibitor, bortezomib. All three are highly effective both in newly diagnosed and relapsed/resistant patients.
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In 2 large multicenter inter national trials the combination of lenalidomide (LEN) and dexamethasone (DEX) was evaluated in comparison to DEX alone. Both trials showed that a percentage of response to LEN/DEX was much greater. In the LEN/DEX group event-free survival was prolonged to 11 months compared to 5 months in the DEX group. This therapy has also shown the efficacy superior to DEX by prolonging time to progression (TTP) and OS. 16, 17 The combination of lenalidomide and dexamethasone as a frontline therapy produced a very high percentage of response -91%.
12 Another new drug bortezomib, which is a proteasome inhibitor, was approved in the US and Europe for resistant/relapsed MM. 13 In multicenter clinical trials bortezomib was more effective than high-dose DEX. The benefits of bortezomib included a longer TTP, a higher CR rate and longer OS. Bortezomib was also very effective in the initial therapy. 18 nonmyeloablative allogeneic transplantation, but they failed to show the superiority of this strategy compared to classical allogeneic or double auto logous transplantation. 9, 10 New drugs The introduction of novel drugs, i.e. thalidomide, lenalidomide and bortezomib, may change this scenario.
11-13 These agents can be used before or after PBSCT aiming to increase the CR and to prolong overall survival (OS). 14, 15 If a patient is not a candidate for an autologous transplant the best combination is melphalan, prednisone and thalidomide, as it was shown by the Italian and French myeloma study groups.
9,10 High-dose dexamethasone is often used in older patients who may be unable to tolerate thalidomide and melphalan.
Treatment for relapsed/refractory multiple myeloma
Therapy for relapsed/refractory diseases are usually based on combinations of new drugs like thalidomide, bortezomib and lenalidomide. 19 In the near future treatment strategies will be tailored based on prognostic factors, genetic background and host features. The addition of novel and conventional agents to the standard treatment with lenalidomide, thalidomide and bortezomib has changed a therapeutic para digm in MM. Future studies will show whether high percentages of positive response to novel drugs will translate into the improvement of overall survival. 
